Hayward
UK needs tighter coronavirus rules to avert catastrophe – epidemiologist
Britain’s government needs to bring in tighter coronavirus lockdown rules to avert a fresh wave of deaths from a new strain of the disease, a leading epidemiologist and government adviser warns. Britain reported 41,385 new COVID cases on Monday, the highest number since testing became widely available in the middle of 2020, and English hospitals say they have more COVID patients than during the first wave of the pandemic in April. “We are entering a very dangerous new phase of the pandemic, and we’re going to need decisive early national action to prevent a catastrophe in January and February,” said Andrew Hayward, professor of infectious disease epidemiology at University College London, on Tuesday. More than 71,000 people in Britain have died within 28 days of a positive test for the dis...
US election: Republicans hold back Democrats, narrowing path to Senate control
The battle for power in the Senate tightened into Wednesday as Democrats picked up a seat in Colorado, but suffered a setback in Alabama, and Republicans held their own in high-profile races in South Carolina, Iowa, Texas and Kansas, dramatically narrowing the political map. Republicans fought to retain their Senate majority by turning back a surge of Democrats challenging allies of President Donald Trump, and the Democrats’ various paths to seizing control were growing more limited. With several contests still too early to call, and one Georgia race heading to a January runoff, the final verdict is expected to drag on. Democrats gained a seat when ex-Gov. John Hickenlooper ousted GOP Sen. Cory Gardner in Colorado, a must-win to flip the Senate, but couldn’t hold on in Alabama, where forme...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
